IL-37 Shows Protective Role in Inflammatory Bowel Disease and Colitis-Associated Cancer
IL-37 is upregulated in inflammatory bowel disease and colitis-associated cancer, exerting protective anti-inflammatory effects.
Phase III
colorectal cancer treatments
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The upregulation of IL-37 in inflammatory bowel disease (IBD) and colitis-associated cancer presents a significant opportunity for therapeutic innovation. As IL-37 demonstrates protective anti-inflammatory effects, it may become a focal point for drug development strategies in gastroenterology.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor ongoing research and clinical trials targeting IL-37 in IBD and colorectal cancer.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.